Last updated: February 28, 2026
What is MAXALT's Current Formulation?
MAXALT (rizatriptan benzoate) is a prescription medication for acute migraine treatment. Its approved formulation is a rapidly dissolving orally disintegrating tablet (ODT), designed for fast absorption. The formulation typically contains excipients such as lactose monohydrate, microcrystalline cellulose, crospovidone, sodium starch glycolate, citric acid, and flavors. These excipients support rapid disintegration, stability, and palatability.
What Role Do Excipients Play in MAXALT's Formulation?
Excipients in MAXALT fulfill multiple functions:
- Disintegrants (crospovidone, sodium starch glycolate): Facilitate rapid breakup of the tablet in saliva or gastrointestinal fluids.
- Binders (microcrystalline cellulose): Ensure tablet integrity during manufacturing.
- Fillers (lactose monohydrate): Provide bulk to the formulation.
- Flavorants and sweeteners: Improve patient compliance by masking bitterness.
The selection focuses on stability, bioavailability, patient acceptance, and manufacturing efficiency.
How Strong Is the Current Excipient Market for ODTs Like MAXALT?
The global oral disintegrating tablet market was valued at approximately USD 11 billion in 2021. It is projected to grow at a compound annual growth rate (CAGR) of roughly 7% through 2028. Key drivers include a rising prevalence of migraine, increasing demand for patient-friendly formulations, and technological improvements in excipient formulations.
Major excipient suppliers include:
- FMC Corporation (lactose, microcrystalline cellulose)
- JRS Pharma (disintegrants)
- Roquette (fillers, excipients)
- Meggle (flavoring agents)
The solid excipient market for ODTs is expected to expand proportionally with the broader ODT and freeze-dried product markets.
What Opportunities Exist for Excipient Innovation in MAXALT?
1. Alternative Disintegrants:
Replacing traditional disintegrants such as crospovidone with superdisintegrants like vitamin C-based or modified cellulose could enhance disintegration speed and stability.
2. Taste Masking Technologies:
Integrating advanced flavorings or barrier coatings, such as lipid-based flavor encapsulation, enhances palatability, especially critical for pediatric or sensitive patients.
3. Improved Moisture Barriers:
Developing excipients with moisture barriers prolongs shelf life and reduces stability issues, necessary for regionally diverse climates.
4. Customizable Polymers:
Using polymers like polyvinylpyrrolidone (PVP) derivatives could fine-tune disintegration and dissolution properties.
5. Biodegradable Excipients:
Exploring biodegradable or natural excipients aligns with consumer demand for clean-label products.
How Can Excipient Strategy Elevate MAXALT's Market Position?
Adopting innovative excipients can lead to:
- Faster onset of action due to improved disintegration and dissolution properties.
- Enhanced taste and patient compliance.
- Extended shelf life and reduced storage constraints.
- Differentiation through formulation stability or natural ingredients.
- Facilitation of alternative administration routes, such as sublingual or buccal films.
What Are the Regulatory Considerations?
Excipient modifications require proof of safety, compatibility, and regulatory approval:
- For FDA approval, new excipients or formulations must conform to 21 CFR Parts 210 and 211.
- Stability data must demonstrate shelf life compliance.
- Excipients used in innovative formulations may necessitate new or supplemental approvals.
Regulatory agencies emphasize the importance of excipient transparency and characterization, especially when introducing novel components.
What Are the Commercial Implications?
- Implementing innovative excipients can command premium pricing in targeted markets.
- Use of natural or biodegradable excipients aligns with clean-label trends, expanding market share.
- Strategic partnerships with excipient suppliers can reduce costs and secure supply chains.
- Rolling out formulations with improved stability and palatability can increase patient adherence and brand loyalty.
- Post-approval changes involving excipients often require regulatory filings but can improve product positioning.
Summary of Key Data Points
| Aspect |
Details |
| Market Value (2021) |
USD 11 billion (global ODT market) |
| CAGR |
7% (2022–2028) |
| Major Excipients |
Lactose monohydrate, microcrystalline cellulose, crospovidone, sodium starch glycolate |
| Launch Year of MAXALT ODT |
2004 (FDA approval) |
| Regulatory Framework |
21 CFR Parts 210 and 211; NDA and SNDA filings |
Key Takeaways
- MAXALT’s excipient strategy centers on rapid disintegration, stability, and flavor masking.
- Innovation opportunities include superdisintegrants, natural excipients, and moisture barriers.
- Market growth supports expanding excipient innovations aligned with patient preferences and regulatory standards.
- Differentiation via excipient innovation can foster higher margins, enhanced compliance, and market share.
FAQs
1. What excipients are critical in MAXALT's current formulation?
Lactose monohydrate, microcrystalline cellulose, crospovidone, sodium starch glycolate, and flavoring agents are primary excipients.
2. How can excipient innovation improve MAXALT's efficacy?
By enabling faster disintegration and dissolution, innovation can lead to quicker onset of analgesic effects.
3. Are natural excipients feasible in MAXALT formulations?
Yes; natural excipients like modified starches or plant-derived disintegrants are gaining approval and can appeal to consumer preferences.
4. What regulatory hurdles exist for incorporating new excipients?
New excipients must demonstrate safety and compatibility, requiring additional testing and regulatory approval.
5. What market trends influence excipient choices for MAXALT?
Growing demand for patient-friendly, stable, and natural formulations drives innovation in excipient selection.
References
[1] Markets and Markets. (2022). Oral disintegrating tablets market analysis. Retrieved from https://www.marketsandmarkets.com
[2] U.S. Food and Drug Administration. (2021). Guidance for Industry: Excipients in new drug applications. Retrieved from https://www.fda.gov
[3] Pharmaceutical Technology Insights. (2020). Innovations in disintegrant excipients for fast-dissolving tablets. Retrieved from https://www.pharmaceutical-technology.com
